Creo Medical Group (LON:CREO) Share Price Crosses Below 50 Day Moving Average – Should You Sell?

Creo Medical Group PLC (LON:CREO) shares passed below its 50-day moving average during trading on Monday . The stock has a 50-day moving average of GBX 13.58 and traded as low as GBX 12.11. Creo Medical Group shares last traded at GBX 13, with a volume of 1,111,256 shares changing hands.

Analyst Ratings Changes

Separately, Shore Capital Group reiterated a “house stock” rating and set a GBX 40 price target on shares of Creo Medical Group in a research report on Thursday, July 23rd.

Creo Medical Group Trading Up 2.0%

The company has a market capitalization of £63.15 million, a price-to-earnings ratio of 13.00 and a beta of 1.56. The firm has a 50-day moving average price of GBX 13.57 and a 200-day moving average price of GBX 13.48. The company has a current ratio of 3.22, a quick ratio of 2.19 and a debt-to-equity ratio of 8.20.

Creo Medical Group (LON:CREO) last announced its quarterly earnings data on Friday, May 22nd. The company reported GBX (0.04) earnings per share for the quarter. Creo Medical Group had a net margin of 88.33% and a return on equity of 9.56%. The firm had revenue of GBX 600 million during the quarter. As a group, sell-side analysts predict that Creo Medical Group PLC will post -10.0800005 EPS for the current year.

Insider Activity at Creo Medical Group

In other Creo Medical Group news, insider Craig Jonathan Gulliford bought 6,250 shares of the company’s stock in a transaction that occurred on Wednesday, July 1st. The shares were acquired at an average cost of GBX 14 per share, for a total transaction of £875. Also, insider Richard John Rees bought 6,250 shares of the business’s stock in a transaction that occurred on Wednesday, July 1st. The shares were acquired at an average cost of GBX 14 per share, with a total value of £875. Insiders own 7.00% of the company’s stock.

About Creo Medical Group

Creo Medical is a medical device company focused on the development and commercialisation of minimally invasive electrosurgical devices, bringing advanced energy to endoscopy.

The Company’s vision is to improve patient outcomes through the development and commercialisation of a suite of electrosurgical medical devices, each enabled by CROMA, powered by Kamaptive. The Group has developed the CROMA powered by Kamaptive full-spectrum adaptive technology to optimise surgical capability and patient outcomes.